All Stories

  1. Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
  2. A bronze statue of the acromegalic giant Rigardus Rijnhout
  3. One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones
  4. Neuropathic foot ulcers in the tallest patients with acromegalic gigantism: a common and significant problem. Historical overview
  5. Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey
  6. The Driver Role of Pathologists in Endocrine Oncology: What Clinicians Seek in Pathology Reports
  7. Unfavorable biological behavior and treatment response of neuroendocrine ovarian metastases of midgut neuroendocrine tumors
  8. Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis
  9. The science behind the relations among cancer, height, growth patterns, and growth hormone axis
  10. A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
  11. Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review
  12. Peptide Receptor Radionuclide Therapy
  13. High rate of Ki‐67 increase in entero‐pancreatic NET relapses after surgery with curative intent
  14. Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment
  15. Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients
  16. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres
  17. Multidisciplinary integrated care pathway for von Hippel–Lindau disease
  18. Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases
  19. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
  20. The possibilities and impossibilities of treating acromegaly 50 years ago illustrated by the Diane Arbus photograph, A Jewish giant at home with his parents in the Bronx, N.Y. 1970
  21. The Surprising Irish Giant of St. James’s Street by Thomas Rowlandson. The acromegalic giant Patrick Cotter (1760–1806)
  22. Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women
  23. The acromegalic? Giant Samuel MacDonald and the short stature George Cranstoun by John Kay
  24. ENETS standardized (synoptic) reporting in neuroendocrine tumours
  25. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours
  26. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours
  27. A circus postcard showing short statue in a clown and a horse
  28. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group
  29. Aldo Molinari: the wedding of the giant Almiro Crema in Torino
  30. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
  31. High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma
  32. Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
  33. Health-Related Quality of Life in Patients with Multiple Endocrine Neoplasia Type 1
  34. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
  35. Toni Mochty: Bardet Biedl syndrome “avant la lettre”
  36. Importance of Complete Pathology Reporting for Neuroendocrine Carcinoma: WHO Guidelines Are a Good Start but Not Enough
  37. Clémentine Delait (1865–1934), the most famous bearded lady on the continent in the 20th century
  38. Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells
  39. Turning up the heat: Endoscopic Ablation of Pancreatic Neuroendocrine Neoplasms
  40. Response to Prof. Ingo Brink and Prof. Aubalewska-Dydejczyk regarding Their “Letter to the Editor”
  41. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
  42. Unmet Needs in the Field of Neuroendocrine Neoplasms of the Gastrointestinal Tract, Pancreas, and Respiratory System: Reports by the ENETS Group
  43. COMPETITIVE TESTING THE WHO 2010 VS THE WHO 2017 GRADING OF PANCREAS NEUROENDOCRINE NEOPLASIA: DATA FROM A LARGE INTERNATIONAL COHORT STUDY
  44. Melena in a Patient With a Metastasized Neuroendocrine Tumor
  45. Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study
  46. Long-Term Natural Course of Small Nonfunctional Pancreatic Neuroendocrine Tumors in MEN1—Results From the Dutch MEN1 Study Group
  47. Rare NOX3 Variants Confer Susceptibility to Agranulocytosis During Thyrostatic Treatment of Graves' Disease
  48. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours
  49. Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
  50. In memoriam: Dirk J Kwekkeboom (1958–2017)
  51. Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality
  52. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors
  53. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents
  54. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy
  55. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors
  56. Effect of a single dose vitamin D3 on postprandial arterial stiffness and inflammation in vitamin D deficient women
  57. Pareidolia in Neuroendocrinology: A Pituitary Macroadenoma Resembling “Big Bird”
  58. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells
  59. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms
  60. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms
  61. Molecular Imaging of Pituitary Pathology
  62. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
  63. The History of Acromegaly
  64. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1
  65. Heroes in endocrinology: Nobel Prizes
  66. GEP-NETS update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs)
  67. Chromogranin A, Ki-67 index and IGF-related genes in patients with neuroendocrine tumors
  68. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate
  69. Obesity, diabetes mellitus, and cancer
  70. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas
  71. Improved Control of Severe Hypoglycemia in Patients with Malignant Insulinomas by Peptide Receptor Radionuclide Therapy